文献速递胸部肿瘤放疗放疗物理与技术

超深度二代测序检测根治性放疗期间早期循环肿瘤DNA动力学的可行性研究

Early circulating tumour DNA kinetics measured by ultra-deep next-generation sequencing during radical radiotherapy for non-small cell lung cancer: a feasibility study.
PubMed 文献 · Radiat Oncol · 2020-05-29

本研究前瞻性纳入接受根治性放疗的局部晚期非小细胞肺癌患者,在放疗第一周内连续采血,用超深度二代测序检测循环肿瘤DNA早期动力学。所有患者均可检出肿瘤特异性突变,2例在72小时出现ctDNA短暂升高,7天时较基线下降但差异无统计学意义(p=0.4627)。研究提示该检测方案可行,ctDNA动力学作为放疗预测生物标志物仍需进一步研究。

要点

  • 根治性放疗第一周内连续采血行超深度二代测序检测ctDNA是可行的。
  • 所有患者均检出肿瘤特异性突变,变异等位基因频率范围为0.05-3.35%。
  • 7天时ctDNA较基线下降但无统计学意义(p=0.4627)。

核心结论

  • 在局部晚期非小细胞肺癌根治性放疗患者中,应用ctDNA优化的二代测序方案在指定时间点检测是可行的。

研究设计与样本

  • 前瞻性可行性研究,纳入经CT/PET分期的局部晚期非小细胞肺癌患者,放疗第一周内连续静脉采血,所有患者接受55Gy分20次放疗。
  • 血浆样本使用Roche AVENIO Expanded试剂盒处理,覆盖77个基因。

主要发现

  • 所有患者均检出肿瘤特异性突变,其中1例检出1个、1例检出2个、1例检出3个突变。
  • 突变变异等位基因频率范围为0.05-3.35%。
  • 2例患者在72小时时间点ctDNA水平较基线出现短暂升高。
  • 所有患者7天时ctDNA水平较基线下降,但差异无统计学意义(p=0.4627)。

临床怎么用

  • 该研究为小样本可行性探索,尚不能将ctDNA动力学常规用于放疗决策。
  • 放疗期间连续采血行超深度二代测序在局部晚期非小细胞肺癌患者中操作可行。

局限性

  • 研究为小样本、同质性队列的可行性研究。
  • 7天时ctDNA下降无统计学意义,尚需研究评估ctDNA动力学作为放疗预测生物标志物的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The evaluation of circulating tumour DNA (ctDNA) from clinical blood samples, liquid biopsy, offers several diagnostic advantages compared with traditional tissue biopsy, such as shorter processing time, reduced patient risk and the opportunity to assess tumour heterogeneity. The historically poor sensitivity of ctDNA testing, has restricted its integration into routine clinical practice for non-metastatic disease. The early kinetics of ctDNA during radical radiotherapy for localised NSCLC have not been described with ultra-deep next generation sequencing previously. MATERIALS AND METHODS: Patients with CT/PET-staged locally advanced, NSCLC prospectively consented to undergo serial venepuncture during the first week of radical radiotherapy alone. All patients received 55Gy in 20 fractions. Plasma samples were processed using the commercially available Roche AVENIO Expanded kit (Roche Sequencing Solutions, Pleasanton, CA, US) which targets 77 genes. RESULTS: Tumour-specific mutations were found in all patients (1 in 3 patients; 2 in 1 patient, and 3 in 1 patient). The variant allele frequency of these mutations ranged from 0.05-3.35%. In 2 patients there was a transient increase in ctDNA levels at the 72 h timepoint compared to baseline. In all patients there was a non-significant decrease in ctDNA levels at the 7-day timepoint in comparison to baseline (p = 0.4627). CONCLUSION: This study demonstrates the feasibility of applying ctDNA-optimised NGS protocols through specified time-points in a small homogenous cohort of patients with localised lung cancer treated with radiotherapy. Studies are required to assess ctDNA kinetics as a predictive biomarker in radiotherapy. Priming tumours for liquid biopsy using radiation warrants further exploration.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Walls GM, McConnell L, McAleese J, et al. Early circulating tumour DNA kinetics measured by ultra-deep next-generation sequencing during radical radiotherapy for non-small cell lung cancer: a feasibility study. Radiat Oncol. 2020. PMID: 32471446. doi:10.1186/s13014-020-01583-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。